

LIST OF CITATIONS

Puneet Agarwal:

- Chan CK, Seo EY, Chen JY, et al. Identification and specification of the mouse skeletal stem cell. *Cell*. 2015 Jan 15;160(1-2):285-98
- Zhang B1, Ho YW, Huang Q, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. *Cancer Cell*. 2012 Apr 17;21(4):577-92

Hycienth Ahaneku:

- Ahaneku H, Ross MW, Nyoni JE, et al. Depression and HIV risk among men who have sex with men in Tanzania. *AIDS Care*. 2016; 28 (sup1):140-147.
- Ajumobi AB, Malakouti M, Bullen A, et al. YouTube™ as a source of instructional videos on bowel preparation: a content analysis. *J Cancer Educ*. 2015; Jul 30

Mohammad Azam:

- Kesarwani M, Huber E, Kincaid Z, et al. A method for screening and validation of resistant mutations against kinase inhibitors. *J Vis Exp*. 2014 Dec 7;(94)
- Kesarwani M, Huber E, Kincaid Z, et al. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. *Sci Rep*. 2015 Sep 30;5:14538

John Barrett:

- Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. *Blood*. 2015 May 21;125(21):3230-5
- Jain NA, Ito S, Tian X, Barrett AJ, et al. Clinical and biological predictors of outcome following relapse of CML post-allo-transplant. *Bone Marrow Transplant*. 2015 Feb;50(2):189-96
- Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. *Blood*. 2016 May 19;127(20):2427-38

Ravi Bhatia:

- Zhang B, Li L, Ho Y, et al. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells. *J Clin Invest*. 2016 Mar 1;126(3):975-91
- Bowers M, Zhang B, Ho Y, et al. Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development. *Blood*. 2015 Apr 23;125(17):2678-88
- Agarwal P, Bhatia R. Influence of bone marrow microenvironment on leukemic stem cells: Breaking up an intimate relationship. *Adv Cancer Res*. 2015; 127: 227-52

Massimiliano Bonifacio:

- Breccia M, Efficace F, Sica S, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. *Leuk Res*. 2015;39(10):1055-1059
- Bonifacio M, Binotto G, Maino E, et al. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced possibility of subsequent optimal response. *Haematologica*. 2015;100(8):e299-301
- Tiribelli M, Binotto G, Calistri E, et al. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favourable response to frontline imatinib therapy. *Am J Hematol*. 2015;90(7):e135-137

Dominique Bonnet:

- Griessinger E, Anjos-Afonso F, Vargatftig J, et al. Frequency and dynamics of *ex-vivo* AML-culture initiating cells reflect patients' outcome. *Cancer Res.* 2016; 76(8):2082-6
- Mian S, Rouault-Pierre K, Smith A, et al. SF3B1 mutant MDS initiating-cells may arise from the hematopoietic stem cell compartment. *Nat Comm.* 2015; 6:10004
- Foster K, Lassailly F, Anjos-Afonso F, et al. Different motile behaviors of human hematopoietic stem and progenitor cells at the osteoblastic niche. *Stem Cell Reports.* 2015; 5(5): 690-701

Susan Branford:

- Deininger MW, Hodgson JG, Shah NP et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. *Blood.* 2016;127:703-712
- Parker WT, Yeung DTO, Yeoman AL, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. *Blood.* 2016;127:1870-1880
- Wang PPS, Parker WT, Branford S, et al. BAM-matcher: a tool for rapid NGS sample matching. *Bioinformatics.* 2016

Bing Z Carter:

- Carter B Z, Mak P Y, Mak D H, et al. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. *Oncotarget* 2015;6:30487-99
- Carter B Z, Mak P Y, Chen Y, et al. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. *Oncotarget* 2016

Wenyong Chen:

- Wang Z, Chen CC, Chen WY. CD150⁻ side population defines leukemia stem cells in a BALB/c mouse model of CML and is depleted by genetic loss of SIRT1. *Stem Cells* 2015, 33: 3437–3451
- Roth R, Wang Z, Chen WY. SIRT1 and LSD1 competitively regulate KU70 functions in DNA repair and mutation acquisition in cancer cells. *Oncotarget*; 2016 June 30
- Wang Z and Chen WY. A convenient cell culture model for CML acquired resistance through BCR-ABL mutations. *Methods molecular biology*, Vol. 1465, Shaoguang Li and Haojian Zhang (Eds): *Chronic Myeloid Leukemia*. Springer, 2016

Jorge Cortes:

- Yilmaz M, Lahoti A, O'Brien S, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Cancer.* 2015; 121(21):3894-904
- Cortes JE, Jean Khoury H, Kantarjian H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. *Am J Hematol.* 2016; 91(6):606-16
- Sasaki K, Kantarjian HM, Jain P, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. *Cancer* 2016;122:238-48

Yashodhara Dasgupta:

- Podszycal P, Bartnicka P, Wolczyk M, Kusio-Kobialka M, et al. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. *Cell Cycle.* 2014; 13(23):3727-41
- Dasgupta Y, Koptyra M, Hoser G, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. *Blood.* 2016; 127(17):2321-2143

Gwo-Jen Day:

- Branford S, Fletcher L, Cross NCP, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. *Blood*. 2008; 112: 3330-3338
- Metcalfe P, Gray E, Hawkins R, et al. Proposed 1st WHO international genetic reference panel for the quantification of BCRABL translocation by RQ-PCR, NIBSC code 09/138. World health organization expert committee on biological standardization. 2009; WHO/BS/09.2106
- Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia* (2015); 29, 999–1003

Michael Deininger:

- Abraham et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. *Nature*. 2016;534(7607):341-6
- Radich et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc Natl Acad Sci U S A*. 2006;103(8):2794-9
- Eiring et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. *Leukemia*. 2015;29(3):586-97

Marc Delord:

- Coudé MM, Braun T, Berrou J, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. *Oncotarget*. 2015;6:17698–17712
- Delord M, Genin E. Multiple imputation for competing risks regression with interval censored data *journal of statistical computation and simulation*. 2015
- Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients. *Blood* 2016 Aug 11;128(6):774-82.

Young Rok Do:

- Kim SH, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. *Haematologica*. 2014 Jul;99(7):1191-6
- Park JS, Lee SE, Jeong SH, et al. Change of health-related profiles after imatinib cessation in chronic phase chronic myeloid leukemia patients. *Leuk Lymphoma*. 2015 May 7:1-24
- Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. *Haematologica*. 2016 Jun;101(6):717-23

Laura Eadie:

- Eadie LN, Dang P, Saunders VA, et al. The clinical significance of *ABCB1* overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. *Leukemia*. 2016 Jul 15.
- Eadie LN, Hughes TP, White DL. The clinical significance of early imatinib induced *ABCB1* overexpression in chronic phase CML patients: A TIDEL II sub-study. *Blood*. 2015;126(23):348
- Eadie LN, Saunders VA, Leclercq TM, et al. The allosteric inhibitor ABL001 is susceptible to resistance in vitro mediated by overexpression of the drug efflux transporters *ABCB1* and *ABCG2*. *Blood*. 2015;126(23):4841
- Eadie LN, Hughes TP, White DL. *ABCB1* overexpression is a key initiator of resistance to the tyrosine kinase inhibitors nilotinib, imatinib and dasatinib. *PLoS One*. *PLoS One*. 2016 Aug 18;11(8):e0161470.

Anna Eiring:

- Wagle M, Eiring AM, Wongchenko M, et al. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. *Leukemia* 2016;30(7):1493-501
- Eiring AM, Khorashad JS, Anderson DJ, et al. b-catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. *Leukemia* 2015;29(12):2328-37
- Eiring AM, Page BD, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. *Leukemia* 2015;29(3):586-97

Carlo Gambacorti-Passerini:

- Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. *Am J Hematol.* 2015 Sep;90(9):755-68
- Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. *Am J Hematol.* 2015 Oct;90(10):910-4
- Gambacorti-Passerini C, Piazza R. Imatinib -- A new tyrosine kinase inhibitor for first-line treatment of chronic myeloid leukemia in 2015. *JAMA Oncol.* 2015 May;1(2):143-4
- Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood.* 2013 May 30;121(22):4439-42
- Viganò I, Di Giacomo N, Bozzani, et al. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. *Am J Hematol.* 2014 Oct;89(10):E184-7
- Gambacorti-Passerini C, Piazza R. How I treat newly diagnosed chronic myeloid leukemia in 2015. *Am J Hematol.* 2015 Feb;90(2):156-61
- Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. *J Natl Cancer Inst.* 2011 Apr 6;103(7):553-61
- Cortes JE, Jean Khoury H, Kantarjian H, et al. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. *Am J Hematol.* 2016 Jun;91(6):606-16

Stuart Goldberg:

- Khoury HJ, Goldberg SL, Mauro MJ, et al. Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. *Clin Lymph Myeloma Leuk* 2016; 16: 341 -349
- Goldberg SL. Monitoring chronic myeloid leukemia in the real world: Gaps and opportunities. *Clin Lymph Myeloma Leuk* 2015; 15:711-714
- Goldberg SL, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. *Blood* 2015; 126:1584 abstract

Elodie Grockowiak:

- Laperrousaz B, Jeanpierre S, Sagorny K et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. *Blood.* 2013 Nov 28;122(23):3767-77

François Guilhot:

- Guilhot J, Baccarani M, Clark R, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood* 2012;119:5963-71.
- Guilhot J, Preudhomme C, Mahon FX, et al. Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. *Cancer*. 2015;121:490-7.
- Guilhot F. Cytogenetic in CML: more important than you think. *Blood* 2016; 127: 2661-62

John Groffen:

- Fei F, Joo EJ, Tarighat SS, et al. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3. *Oncotarget*. 2015;6(13):11378-94
- Fei F, Lim M, George AA, et al. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. *Leukemia*. 2015;29(4):788-97

Oliver Hantschel:

- Wojcik J, Lamontanara AJ, Grabe G, et al. Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface. *J Biol Chem*. 2016 Apr 15;291(16):8836-47
- Maxson JE, Abel ML, Wang J, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. *Cancer Res*. 2016 Jan 1;76(1):127-38
- Lorenz S, Deng P, Hantschel O, et al. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity. *Biochem J*. 2015 Jun 1;468(2):283-91

Nora Heisterkamp:

- Fei F, Joo EJ, Tarighat SS, et al. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3. *Oncotarget*. 2015;6(13):11378-94
- Fei F, Lim M, George AA, et al. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. *Leukemia*. 2015;29(4):788-97

G. Vignir Helgason:

- Karvela M, Baquero P, Kuntz EM, et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. *Autophagy*. 2016 Jun 2;12(6):936-48
- Holyoake TL, Helgason GV. Do we need more drugs for chronic myeloid leukemia? *Immunol Rev*. 2015 Jan;263(1):106-23
- Pellicano F, Scott MT, Helgason GV, et al. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. *Stem Cells*. 2014 Sep;32(9):2324-37

Andreas Hochhaus:

- Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. *J Clin Oncol*. 2016 Jul 10;34(20):2333-40
- Saussele S, Richter J, Hochhaus A et al. The concept of treatment-free remission in chronic myeloid leukemia.; *Leukemia*. 2016 Jun 3
- Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*. 2016 Aug;30(8):1648-71

- Cross NC, White HE, Ernst T et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. *Leukemia*. 2016 Jun 3
- Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*. 2016 May;30(5):1044-54
- Hochhaus A, Rosti G, Cross NC, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. *Leukemia*. 2016 Jan;30(1):57-64

Tessa Holyoake:

- Abraham SA, Hopcroft LE, Carrick E, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. *Nature*. 2016 Jun 8;534(7607):341-6
- Sinclair A, Park L, Shah M, et al. CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. *Blood*. 2016 May 24
- Karvela M, Baquero P, Kuntz EM, et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. *Autophagy*. 2016 Jun 2;12(6):936-48

Tim P. Hughes:

- Eadie LN, Dang P, Saunders VA, et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. *Leukemia* June 2016
- Nievergall E, Reynolds J, Kok C, et al. TGF- α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. *Leukemia* June 2016 30(6) 1263-1272
- Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. *BLOOD* 2016-01-694265
- Parker WT, Yeung DT, Yeoman AL, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. *BLOOD* April 2016 Vol 127 1870 -1880
- Yeung DT, Tang C, Vidovic L, et al. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. *BLOOD* 2015 Dec 126 (25) 2720-2723

Brian Huntly:

- Giotopoulos G, Van der Weyden L, Osaki H, et al. A novel murine model identifies cooperating mutations and therapeutic targets critical for the progression of chronic myeloid leukemia (CML). *J Exp Med*. 2015 Aug 24
- Fong CY, Gilan O, Huntly BJP et al. BET inhibitor resistance emerges from leukemia stem cells. *Nature*. 2015 Sep 24;525(7570):538-42
- Grimwade D, Ivey A, Huntly BJP. Molecular landscape of acute myeloid leukemia and its clinical relevance. *Blood*. 2016 Jan 7;127(1):29-41

Lorna Jackson:

- Horne G, Jackson L, Helgason V, et al. Stem cell guardians - Old and new perspectives in LSC biology. *Curr Drug Targets*. 2016 Jul 11

Qian Jiang:

- Jiang Q, Gale RP. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. *J Cancer Res Clin Oncol*. 2016 Jul;142(7):1549-55

- Jiang Q, Liu ZC, Zhang SX, et al. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2016 Jul;142(7):1539-47
- Jiang Q, Qin YZ, Lai YY, et al. Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance. *Leuk Lymphoma*. 2015 Jul;56(7):2075-81

Hagop Kantarjian

- Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N Engl J Med* 346(9):645-52, 2/2002
- Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N Engl J Med* 354(24):2542-51, 6/2006
- Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 362(24):2260-70, 6/2010. e-Pub 6/2010
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med* 362(24):2251-9, 6/2010. e-Pub 6/2010
- Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J. Med*. 369(19): 1783-96; 11/2013

Dennis Dong Hwan Kim

- Kim T, Yoshida K, Kim YK. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression. *Leukemia* 2016;30(2):295-302
- Ahn JS, Kim HJ, Kim YK. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. *Haematologica* 2015;100(9);e351-3

Daniela Krause:

- Krause DS, Scadden DT. A hostel for the hostile: The stem cell niche in haematological neoplasms *Haematologica*. 2015 Nov;100(11):1376-87
- Rabenhorst U, Thalheimer F, Gerlach K, et al. Single-stranded DNA-binding transcriptional regulator FUBP1 is essential for fetal and adult hematopoietic stem cell self-renewal. *Cell Rep*. 2015 Jun 30;11(12):1847-55
- Naka K, Ishihara K, Jomen Y, et al. Novel oral transforming growth factor- β signaling inhibitor EW-7197 eradicates CML-initiating cells. *Cancer Sci*. 2016 Feb;107(2):140-8

François-Xavier Mahon:

- Etienne G, Guilhot J, Réa D, et al. Long-term follow-up of the French stop imatinib study (STIM1) in chronic myeloid leukemia patients. *J Clin Oncol*. 2016 in press
- Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. *Cancer Med*. 2016 Jul 1
- Charaf L, Mahon FX, Lamrissi-Garcia I, et al. Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells. *Leukemia*. 2016 Jun 10
- Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. *Leukemia*. 2016 Aug;30(8):1638-47

Giovanni Martinelli:

- Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. *Blood*. 126(3):291-9, 2015

- White H, Deprez L, Corbisier P, et al. A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. *Leukemia* 29(2):369-76, 2015.
- Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. *N Engl J Med*. 2016 Jun 12

Michael Mauro:

- Gotlib J, Kluin-Nelemans HC, George TI et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. *N Engl J Med*. 2016 Jun 30;374(26):2530-41
- Khoury HJ, Goldberg SL, Mauro MJ et al. Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. *Clin Lymphoma Myeloma Leuk*. 2016 Jun;16(6):341-349
- Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. *Am J Hematol*. 2015 Nov;90(11):1060-4

Adam Mead:

- Drissen R, Buza-Vidas N, Woll P, et al. Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. *Nat Immunol*. 2016;17(6):666-76
- Psaila B, Barkas N, Iskander D, et al. Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. *Genome Biol*. 2016;17(1):83
- Wills QF, Mead AJ. Application of single-cell genomics in cancer: promise and challenges. *Hum Mol Genet*. 2015;24(R1):R74-84

Hind Medyouf:

- Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. *Blood*. 2016 Jun 6
- Bulycheva E, Rauner M, Medyouf H, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies. *Leukemia*. 2015 Feb;29(2):259-68
- Medyouf H, Mossner M, Jann JC, et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. *Cell Stem Cell*. 2014 Jun 5;14(6):824-37

Martin Müller:

- Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia*. 2015;29(5):999-1003
- Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. *Blood*. 2015;126(1):42-9
- Cross NC, White HE, Ernst T, et al. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. *Leukemia*. 2016

Chinmay Rajiv Munje:

- Munje C, Hills R K Whetton, et al. Cord blood-derived quiescent CD34⁺ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34⁺ cells. *Gene Expression*. 2015; 16(4): 169-175
- Munje C, Shervington L, Khan Z. et al. Could upregulated Hsp70 protein compensate for the Hsp90 silence induced cell death in glioma cells? *Int. Journal of Brain Science*. 2014; Article ID 652643
- Hole PH, Zabkiewicz J, Munje C et al. ROS overproduction in AML promotes proliferation. *Blood*. 2013; 122(19): 3322-3330

Markus Müschen:

- Shojaee S, Chan LN, Buchner M, et al. PTEN is essential for oncogenic transformation of pre-B cells. *Nature Medicine* 22: 379-387 (2016)
- Chen Z, Shojaee S, Buchner M, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. *Nature* 2015 May 21;521
- Swaminathan S, Klemm L, Park E, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. *Nat Immunol.* 2015 Jul;16(7):766-74
- Geng H, Hurtz C, Lenz KB et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. *Cancer Cell.* 2015 Mar 9;27(3):409-25
- Shojaee S, Caeser R, Buchner M et al. Erk feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. *Cancer Cell.* 2015 Jul 13;28(1):114-28

Pratik Nagaria:

- Robert C, Nagaria PK, Pawar N, et al. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. *Leuk Res* 2016;45:14-23
- Nagaria P, Robert C, Rassool FV. DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity. *Biochim Biophys Acta* 2013;1830:2345-53
- Nagaria P, Svilar D, Brown AR, et al. SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress. *Mutat Res* 2012;743-744:26-32

Rihab Nasr:

- Nasr RR, Hmadi RA, El-Eit RM et al. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model. *Int J Cancer.* 2015; 137(3): 698-709
- Nassar FG, El Sabban M, Zgheib NK, et al. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: A pilot study. *PLoS One.* 2014; 9(9): e107566
- El Eit R, Iskandarani A, Saliba J, et al. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. *Int J Cancer.* 2014; 134(4): 988-96

King Pan Ng:

- Chau BL, Ng KP, Li KK et al. RGG boxes within the TET/FET family of RNA-binding proteins are functionally distinct. *Transcription.* 2016: e1183071
- Ko TK, Chin HS, Chuah CT et al. The BIM deletion polymorphism: a paradigm of a permissive interaction between germline and acquired TKI resistance factors in CML. *Oncotarget,* 2016; 7(3):2721-33

Danilo Perrotti:

- Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. *J Clin Invest.* 2007 Sep;117(9):2408-21.
- Perrotti D, Silvestri G, Stramucci L, et al. Cellular and molecular networks in chronic myeloid leukemia: the leukemic stem, progenitor and stromal cell interplay. *Curr Drug Targets.* 2016 Jun 14.
- Ciccone M, Calin GA, Perrotti D. From the biology of PP2A to the PADs for therapy of hematologic malignancies. *Front Oncol.* 2015 Feb 16;5:21.

Javier Pinilla-Ibarz:

- Sweet K, Pinilla-Ibarz J. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. *Crit Rev Oncol Hematol*. 2016 Jul;103:99-108
- Brayer J, Lancet JE, Powers J, et al. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. *Am J Hematol* 2015 Jul; 90: (7) 602-607
- Pinilla-Ibarz J, Sweet K, Emole J, et al. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. *Anticancer Res* 2015 Dec; 35: (12) 6355-6364
- Fradley MG, Pinilla-Ibarz J. Arrhythmic complications of tyrosine kinase inhibitors. *Future Cardiol* 2015 Jul; 11: (4) 395-399

Katarzyna Piwocka:

- Mamińska A, Bartosik A, Banach-Orłowska M, et al. ESCRT proteins restrict constitutive NF- κ B signaling by trafficking cytokine receptors. *Sci Signal*. 2016; 9(411):ra8
- Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, et al. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation. *Cell Cycle* 2014; 13: 3727-41
- Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, et al. The PERK-eIF2 α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. *Cell Cycle* 2012; 11: 4069-78
- Piwocka K, Vejda S, Cotter TG, et al. Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling. *Blood* 2006; 107: 4003-10

Sabrina Prici:

- Brambilla L, Genini D, Laurini E, et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3). *Mol Oncol*. 2015;9:1194-206
- Wei T, Chen C, Liu J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. *Proc Natl Acad Sci USA*. 2015;112:2978-83
- Prici S, Cortelazzi B, Dal Col V, et al. Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. *Mol Oncol*. 2015;9:389-97

Stephane Prost:

- Lewis M, Copland M, Soverini S, et al. What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? *Hematological oncology*. 2016 Jul 19
- Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR γ agonists. *Nature* 2015; 525(7569): 380-3
- Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR γ agonists. *Nature*. 2015 Sep 17;525(7569):380-3
- Prost S, Le Dantec M, Auge S, et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPAR γ /STAT5 signaling pathway in macaques. *J Clin Invest*. 2008 May;118(5):1765-75

Jerry Radich:

- Sala-Torra O, Beppu L, Smith J, et al. Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried spots. *Blood* 127: 2773-2774, 2016

- Brehme M, Koschmieder S, Montazeri M, et al. Combined population and entropy modeling supports patient stratification in chronic myeloid leukemia. *Sci Rep*. 2016 Apr 6;6:24057.
- Rochau U, Sroczynski G, Wolf D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: A decision analysis. *Leukemia Research and Treatment, Leukemia Research and Treatment; Volume 2015*
- McDougall J, Ramsey S, Radich J. What happens when imatinib becomes generic? *J Natl Compr Canc Netw*, in press, 2016

Feyruz Rassool:

- Robert C, Nagaria PK, Pawar N, et al. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. *Leuk Res* 2016;45:14-23
- Pratik Nagaria, Carine Robert, et al. High-fidelity reprogrammed Human iPSCs have a high efficacy of DNA repair and resemble hESCs in their MYC transcriptional signature". In press *Stem Cell International*
- Muvarak N, Chowdhury K, Xia L, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents – A potential therapy for cancer. *Cancer Cell* (in press)

Delphine Réa:

- Mahon FX, Réa D, Guilhot J, et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol*. 2010; 11: 1029-1035
- Réa D, Rousselot P, Guilhot J, et al. Curing chronic myeloid leukemia. *Curr Hematol Malig Rep*. 2012; 7: 103-118
- Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. *J Clin Oncol*. 2014; 32: 424-430
- Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. *Oncotarget*. 2016 May 5

Anthony Rongvaux:

- Rongvaux A, Willinger T, Takizawa H, et al. Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. *Proc Natl Acad Sci U S A*. 2011 Feb 8;108(6):2378-83
- Rongvaux A, Takizawa H, Strowig T et al. Human hemato-lymphoid system mice: current use and future potential for medicine. *Annu Rev Immunol*. 2013;31:635-74
- Rongvaux A, Willinger T, Martinek J et al. Development and function of human innate immune cells in a humanized mouse model. *Nat Biotechnol*. 2014 Apr;32(4):364-72

Philippe Rousselot:

- Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. *Oncotarget*. 2016 May 5.
- Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR γ agonists. *Nature*. 2015 Sep 17;525(7569):380-3.
- Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. *J Clin Oncol*. 2014 Feb 10;32(5):424-30.

Koji Sasaki:

- Sasaki K, Kantarjian H, Jabbour E et al. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. *Haematologica*. 2016
- Sasaki K, Kantarjian HM, Jain P et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. *Cancer*. 2016;122(2):238-48
- Sasaki K, Strom SS, O'Brien S et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. *The Lancet Haematology*. 2015;2(5):e186-93

Rahul Satija:

- Macosko EZ, Basu A, Satija R, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. *Cell* 2015; 161: 1202–14
- Satija R, Farrell JA, Gennert D, et al. Spatial reconstruction of single-cell gene expression data. *Nat Biotechnol* 2015; 33: 495–502
- Satija R, Shalek AK. Heterogeneity in immune responses: from populations to single cells. *Trends Immunol* 2014; 35: 219–29

Susanne Saussele:

- Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. *Leukemia*. 2016 Jun 3
- Miranda MB, Lauseker M, Kraus MP, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. *Leukemia* 2016; 30(6): 1255-62
- Saussele S, Krauss MP, Hehlmann R, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. *Blood* 2015; 126(1): 42-9

Mirle Schemionek:

- Schemionek M, Herrmann O, Reher MM, et al. Mtss1 is a critical epigenetically regulated tumor suppressor in CML. *Leukemia* 2016; 30(4): 823-32.
- Schemionek M, Kharabi Masouleh B, Klaile Y, et al. Identification of the adapter molecule MTSS1 as a potential oncogene-specific tumor suppressor in acute myeloid leukemia. *PLoS one* 2015; 10(5): e0125783.
- Kirschner MM, Schemionek M, Schubert C, et al. Dissecting genomic aberrations in myeloproliferative neoplasms by multiplex-PCR and next generation sequencing. *PLoS one* 2015; 10(4): e0123476.

Charles Schiffer:

- Schiffer CA, Cortes J, Hochhaus A, et al. Lymphocytosis following treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. *Cancer* 122:1398-407, 2016
- Shah N, Rousselot P, Schiffer C et al. Dasatinib in imatinib-resistant or intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. *Am J Hematology* 2016. (in press)

Jan Jacob Schuringa:

- Sontakke P, Carretta M, Jaques J, et al. Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model. *Leukemia* 2016. May 17
- Van den Boom V, Maat H, Geugien M, et al. Non-canonical PRC1.1 Targets active genes independent of H3K27me3 and is essential for leukemogenesis. *Cell Rep* 2016;14(2):332-346
- Sontakke P, Koczula KM, Jaques J, et al. Hypoxia-like signatures induced by BCR-ABL potentially alter the glutamine uptake for maintaining oxidative phosphorylation. *PLoS One* 2016;11(4):e0153226

- Horton SJ, Jaques J, Woolthuis C et al. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. *Leukemia* 2012;5:1116-1126

Tomasz Skorski:

- Huang F, Goyal N, Sullivan K, et al. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. *Nucleic Acids Res* 2016
- Dasgupta Y, Koptyra M, Hoser G, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. *Blood* 2016;127:2131-43
- Sullivan K, Cramer-Morales K, McElroy DL, et al. Identification of a small molecule Inhibitor of RAD52 by structure-based selection. *PLoS One* 2016;11:e0147230
- Chandramouly G, McDevitt S, Sullivan K, et al. Small-molecule disruption of RAD52 rings as a mechanism for precision medicine in BRCA-deficient cancers. *Chem Biol* 2015;22:1491-504

Simona Soverini:

- Soverini S, De Benedittis C, Mancini M, et al. Best practices in chronic myeloid leukemia monitoring and management. *Oncologist*. 2016 May;21(5):626-33
- Soverini S, De Benedittis C, Machova Polakova KM, et al. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget*. 2016 Mar 9
- Soverini S, De Benedittis C, Papayannidis C, et al. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. *Leukemia*. 2016 Feb 12

Tomasz Stoklosa:

- Dasgupta Y, Koptyra M, Hoser G, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. *Blood*. 2016; 127(17):2131-43
- Glodkowska-Mrowka E, Manda-Handzlik A, Stelmaszczyk-Emmel A, et al. PPAR γ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells. *Blood Cancer J*. 2016; 6:e377
- Dabek B, Kram A, Kubrak J, et al. A rare mutation in a rare tumor--SMARCB1-deficient malignant glomus tumor. *Genes Chromosomes Cancer*. 2016; 55(1):107-9

Ana Tari Ashizawa:

- Ohanian M, Ravandi F, Borthakur G, et al. Phase I study of BP1001 (liposomal Grb2 antisense) in patients with hematologic malignancies. *J Clin Oncol* 2016;34 Suppl: Abstract 7010
- Tari Ashizawa A, Cortes JE. Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. *Expert Opin Drug Deliv*. 2015 Jul;12(7):1107-20

Daniel G. Tenen:

- Bararia B, Kwok HS, Welner RS, et al. Acetylation of C/EBP inhibits its granulopoietic function. 2016. *Nature Comm*. 7:10968
- Ye M, Zhang H, Yang H, et al. Hematopoietic differentiation is required for initiation of acute myeloid leukemia. 2015. *Cell Stem Cell* 17:611-623
- Welner RS, Amabile G, Bararia D, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. 2015. *Cancer Cell* 27:671-681

Hein Than:

- Than H, Loh JB, Sum CL, et al. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report. *J Clin Pathol*. 2015 Apr;68(4):318-9

- Xiang W, Cheong JK, Ang SH, et al. Pyruvium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. *Oncotarget*. 2015 Oct 20;6(32):33769-80
- Than H, Chuah C, Ong ST. Molecular mechanism of TKI resistance and potential approaches to overcome resistance (Chapter) in molecular pathogenesis and treatment of chronic myelogenous leukaemia (Springer Japan 2016. ISBN 978-4-431-55713-5)

Luisa Tomasello:

- Bellisola G, Bolomini Vittori M, Cinque G, et al. Unsupervised explorative data analysis of normal human leukocytes and BCR/ABL positive leukemic cells mid-infrared spectra. *Analyst*. 2015 Ju7;140(13):4407-22
- Moratti E, Vezzalini M, Tomasello L, et al. Identification of protein tyrosine phosphatase receptor gamma extracellular domain (SPTPRG) as a natural soluble protein in plasma. *PLoS One*. 2015 Mar 16;10(3):e0119110
- Galvan A, Colombo F, Frullanti E, et al. Germline polymorphisms and survival of lung adenocarcinoma patients: A genome-wide study in two European patient series. *Int J Cancer*. 2015 Mar 1;136(5):E262-71

Paolo Vigneri:

- Giallongo C, Romano A, Parrinello NL, et al. Mesenchymal stem cells (MSC) regulate activation of granulocyte-like myeloid derived suppressor cells (G-MDSC) in chronic myeloid leukemia patients. *PLoS One* 2016;11(7):e0158392.
- Manzella L, Tirro E, Pennisi MS, et al. Roles of interferon regulatory factors in chronic myeloid leukemia. *Curr Cancer Drug Targets* 2016.
- Stagno F, Stella S, Spitaleri A, et al. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. *Expert Rev Anticancer Ther* 2016;16(3):273-8.

Wei Wang:

- Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Blood* 2016; 127(22): 2742-50
- Wang W, Cortes JE, Lin P, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. *Blood* 2015; 126(14): 1699-706
- Wang W, Cortes JE, Lin P, et al. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. *Leukemia* 2015; 29(11): 2263-6

Claudia Waskow:

- Mende N, et al. CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo. *J Exp Med*, 2015. 212(8): p. 1171-83
- Cosgun KN, Rahmig S, Mende N, et al. Kit Regulates HSC Engraftment across the Human-Mouse Species Barrier. *Cell Stem Cell*, 2014. 15(2): p. 227-38
- Rahmig S, Kronstein-Wiedemann R, Fohgrub J, et al. Improved human erythropoiesis and platelet formation in humanized NSGW41 mice. *Stem Cell Reports*, 2016. in press

Robert S. Welner:

- Welner RS, Amabile G, Bararia D, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. *Cancer cell* 2015; 27 (5): 671-81
- Amabile G, Di Ruscio A, Muller F, et al. Dissecting the role of aberrant DNA methylation in human leukaemia. *Nature communications* 2015; 6: 7091

- Bararia D, Kwok HS, Welner RS, and al. Acetylation of C/EBPalpha inhibits its granulopoietic function. Nature communications 2016; 7: 10968

Deborah White:

- Schafranek L, Nievergall E, Powell JA, et al. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia. 2015 Jan;29(1):76-85
- Nievergall E, Reynolds J, Kok CH, et al ; Predictive value of TGF- α and IL-6 plasma levels to identify CML patients that fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016 Jun;30(6):1263-72
- Eadie LN, Dang P, Yeung D, et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2016 Jul 15

Dominik Wolf:

- Rudolph J, Heine A, Quast T, et al. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia. 2016 May 25
- Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition substantially impairs NK cell function in vitro and in patients with myeloproliferative neoplasms (MPN) . Cancer Res. 2015 Jun 1;75(11):2187-99
- Wolf D, Wolf AM. CCR 20th anniversary commentary: From regulatory T cells to checkpoint monoclonal antibodies — Immuno-oncology advances clinical cancer research. Clin Cancer Res. 2015 Jun 15;21(12):2657-9